Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)
Brief Summary: This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, \& Warfarin. The expected duration of the study is 24 months.


Options:
A: Arm Label: 1. YM150, Dose W, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 2. YM150, Dose X, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 3. YM150, Dose X, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 4. YM150, Dose Y once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 5. YM150, Dose Y twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 6. YM150, Dose Z, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 7. Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: YM150; Assigned to Arm(s): 1. YM150, Dose W, twice daily, 2. YM150, Dose X, once daily, 3. YM150, Dose X, twice daily, 4. YM150, Dose Y once daily, 5. YM150, Dose Y twice daily, 6. YM150, Dose Z, once daily | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): 7. Warfarin
B: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Apixaban 5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Apixaban 2.5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin sodium | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 5mg BID | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 2.5mg BID | Intervention Type: DRUG; Name: Warfarin sodium; Assigned to Arm(s): Warfarin

Answer: B